NCT06050928 (CALM-CIndU) is a Phase 1 clinical trial of Oral EP262 in Chronic Inducible Urticaria, sponsored by Escient Pharmaceuticals, Inc.

Who is sponsoring NCT06050928?

NCT06050928 is sponsored by Escient Pharmaceuticals, Inc.

What drugs are being tested in NCT06050928?

Interventions in NCT06050928: Oral EP262.

What condition does NCT06050928 study?

NCT06050928 studies Chronic Inducible Urticaria.

Is NCT06050928 still recruiting?

NCT06050928 is currently completed. Last updated 9 December 2024.

Last reviewed 2024-12-09 · How we verify

NCT06050928: CALM-CIndU

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Chronic Inducible Urticaria

Completed Phase 1 Last updated 9 December 2024

What this trial tests

Phase 1 trial testing Oral EP262 in Chronic Inducible Urticaria in 33 participants. Completed in 22 October 2024.

Timeline

30 August 2023

Primary endpoint
22 October 2024

22 October 2024

Quick facts

Lead sponsor	Escient Pharmaceuticals, Inc
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	33
Start date	30 August 2023
Primary completion	22 October 2024
Estimated completion	22 October 2024
Sites	15 locations across Netherlands, Germany, Canada, United States, Spain

Drugs / interventions tested

Oral EP262 — full drug profile →

Conditions studied

Chronic Inducible Urticaria — all drugs for Chronic Inducible Urticaria →

Sponsor

Escient Pharmaceuticals, Inc — full company profile →

Who can join

Adults 18 to 80, any sex, with Chronic Inducible Urticaria. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase 1b trial will evaluate the effects of EP262 in subjects with Chronic Inducible Urticaria (CIndU), including symptomatic dermographism and cold urticaria.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

New insights into chronic inducible urticaria.
Muñoz M, Kiefer LA, Pereira MP, Bizjak M, et al · · 2024 · cited 13× · PMID 39028396 · DOI 10.1007/s11882-024-01160-y
Update on the Treatment of Chronic Spontaneous Urticaria.
Kolkhir P, Fok JS, Kocatürk E, Li PH, et al · · 2025 · cited 10× · PMID 40074986 · DOI 10.1007/s40265-025-02170-4
Therapies for Chronic Spontaneous Urticaria: Present and Future Developments.
Asero R, Calzari P, Vaienti S, Cugno M. · · 2024 · cited 10× · PMID 39598410 · DOI 10.3390/ph17111499
IgE and non-IgE-mediated pathways in anaphylaxis.
Worm M, Pazur K, Morakabati P, Redhu D. · · 2025 · cited 5× · PMID 40802080 · DOI 10.1007/s00281-025-01056-7
No allergy, but mast cells are involved: MRGPRX2 in chronic inflammatory skin diseases.
Metz M. · · 2025 · cited 3× · PMID 39996342 · DOI 10.1111/jdv.20541
Functional heterogeneity of mast cells in cutaneous inflammation: implications for precision medicine.
A S, Ulzii D, Yadamsuren E, Shi J. · · 2025 · cited 1× · PMID 41164192 · DOI 10.3389/fimmu.2025.1680574
Advancements and challenges in the management of chronic inducible urticaria.
Zhang M, Liu J, Zhi Y. · · 2026 · PMID 42112401 · DOI 10.3389/fimmu.2026.1747542
The MRGPRX2 paradigm shift: Redefining mast cell activation pathways in chronic urticaria.
Wu K, Liu J. · · 2026 · PMID 42058742 · DOI 10.5414/alx02618e

Verify or expand the search:

Other trials of Oral EP262

Trials testing the same drug.

NCT06144424 — Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics · Phase 2 · completed
NCT06077773 — Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects Wi · Phase 2 · terminated

Other recruiting trials for Chronic Inducible Urticaria

Currently open trials in the same condition.

NCT06931405 — Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU) · Phase 2 · recruiting
NCT05976243 — A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Ina · Phase 3 · active not recruiting

Other Escient Pharmaceuticals, Inc trials

Trials by the same sponsor.

NCT06645704 — An Open-Label Phase 1 Study in Healthy Male Subjects to Investigate the Absorption, Metabolism and Excretion of [14C]-EP · Phase 1 · completed
NCT06144424 — Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics · Phase 2 · completed
NCT06077773 — Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects Wi · Phase 2 · terminated
NCT05525520 — Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing C · Phase 2 · completed
NCT04510090 — Evaluate the Safety, Tolerability, and PK of EP547 in Healthy Subjects and Subjects With Cholestatic or Uremic Pruritus · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06050928 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Escient Pharmaceuticals, Inc
Last refreshed: 9 December 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06050928.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing